Deprescribing of antidiabetic drugs in middle-aged and elderly people with type 2 diabetes mellitus

• Yana D. Prokhorova
• Tatyana Yu. Demidova
• Elena Yu. Gritskevich

Abstract

This study examined the safety and efficacy of canceling or replacing antidiabetic drugs (deprescribing) in patients with type 2 diabetes mellitus (type 2 diabetes) at risk of developing hypoglycemia. Two groups were formed. Group 1 included patients who had previously taken oral glucose-lowering drugs (PADs) of the sulfonylurea group, group 2 included patients who had previously received basic-bolus insulin therapy. The average levels of glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) before the change of therapy in group 2 were higher than in group 1. Using the comparative method, significant differences were revealed between patients in group 1 and group 2: patients receiving PSSP had lower HbA1c (p<0.001) and the average glucose level on admission (p<0.05). After deprescribing, the average level of FPG in group 1 and in group 2 did not show statistically significant differences.

Keywords:deprescribing, type 2 diabetes mellitus, basal-bolus insulin therapy, sulfonylurea, glycated hemoglobin, fasting plasma glucose

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)